332 related articles for article (PubMed ID: 27903276)
1. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.
Selli C; Dixon JM; Sims AH
Breast Cancer Res; 2016 Dec; 18(1):118. PubMed ID: 27903276
[TBL] [Abstract][Full Text] [Related]
2. Endocrine treatment in breast cancer: Cure, resistance and beyond.
Tryfonidis K; Zardavas D; Katzenellenbogen BS; Piccart M
Cancer Treat Rev; 2016 Nov; 50():68-81. PubMed ID: 27643748
[TBL] [Abstract][Full Text] [Related]
3. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
4. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.
De Marchi T; Foekens JA; Umar A; Martens JW
Drug Discov Today; 2016 Jul; 21(7):1181-8. PubMed ID: 27233379
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy in luminal breast cancers.
Lim E; Winer EP
Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
[TBL] [Abstract][Full Text] [Related]
7. Evolution of endocrine adjuvant therapy for early breast cancer.
Lønning PE
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S19-30. PubMed ID: 20374026
[TBL] [Abstract][Full Text] [Related]
8. Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer.
Alfarsi L; Johnston S; Liu DX; Rakha E; Green AR
Histopathology; 2018 Oct; 73(4):545-558. PubMed ID: 29603357
[TBL] [Abstract][Full Text] [Related]
9. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
10. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Yeo B; Dowsett M
Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
[TBL] [Abstract][Full Text] [Related]
12. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
[TBL] [Abstract][Full Text] [Related]
13. Current and future status of adjuvant therapy for breast cancer.
Coleman RE
Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
15. Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?
Reinhardt F; Franken A; Fehm T; Neubauer H
Tumour Biol; 2017 Nov; 39(11):1010428317731511. PubMed ID: 29129161
[TBL] [Abstract][Full Text] [Related]
16. Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.
Reinert T; Gonçalves R; Ellis MJ
Curr Treat Options Oncol; 2018 Apr; 19(5):23. PubMed ID: 29663173
[TBL] [Abstract][Full Text] [Related]
17. The NFkappaB pathway and endocrine-resistant breast cancer.
Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA; Palmer DH; Moon S; Rea DW
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
[TBL] [Abstract][Full Text] [Related]
19. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.
Kai K; Nishimura R; Arima N; Miyayama H; Iwase H
Int J Clin Oncol; 2006 Dec; 11(6):426-33. PubMed ID: 17180510
[TBL] [Abstract][Full Text] [Related]
20. Preoperative endocrine therapy for breast cancer.
Cheung KL; Howell A; Robertson JF
Endocr Relat Cancer; 2000 Sep; 7(3):131-41. PubMed ID: 11021962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
